Association between ankle-brachial index and risk factor profile in patients newly diagnosed with intermittent claudication

Circulation Journal

Volumn 72, Issue 3, 2008, Pages 441-448

  Daskalopoulou, Stella S ^a,b,c   Pathmarajah, Mariasoosai ^a   Kakkos, Stavros K ^a   Daskalopoulos, Marios E ^a   Holloway, P A H ^a   Mikhailidis, Dimitri P ^b   Mayo, Nancy E ^c   Geroulakos, George ^a,d  

^a EALING HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c MCGILL UNIVERSITY   (Canada)

^d CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Ankle brachial index; Intermittent claudication; Peripheral arterial disease; Primary care; Risk factors

Indexed keywords

ANTILIPEMIC AGENT; C REACTIVE PROTEIN; CREATININE; FIBRINOGEN; GLUCOSE; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ANKLE BRACHIAL INDEX; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIET RESTRICTION; DYSLIPIDEMIA; FEMALE; FIBRINOGEN BLOOD LEVEL; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INTERMITTENT CLAUDICATION; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; OUTPATIENT DEPARTMENT; PATIENT REFERRAL; PRIMARY MEDICAL CARE; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SMOKING; VASCULAR SURGERY;

AGED; ANKLE; BRACHIAL ARTERY; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; CREATININE; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; DYSLIPIDEMIAS; FEMALE; FIBRINOGEN; HUMANS; HYPERTENSION; INTERMITTENT CLAUDICATION; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERIPHERAL VASCULAR DISEASES; RISK FACTORS; SMOKING;

EID: 42649133162     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.72.441     Document Type: Article

References (54)

1. Meru AV, Mittra S, Thyagarajan B, Chugh A. Intermittent claudication: An overview. Atherosclerosis 2006; 187: 221-237.
2. Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA 2006; 295: 547-553.
3. Daskalopoulou SS, Daskalopoulos ME, Liapis CD, Mikhailidis DP. Peripheral arterial disease: A missed opportunity to administer statins so as to reduce cardiac morbidity and mortality. Curr Med Chem 2005; 12: 443-452.
4. Li J, Luo Y, Xu Y, Yang J, Zheng L, Hasimu B, et al. Risk factors of peripheral arterial disease and relationship between low ankle-brachial index and mortality from all-cause and cardiovascular disease in Chinese patients with type 2 diabetes. Circ J 2007; 71: 377-381.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
6. British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91(Suppl 5): v1-v52.
7. Tapp RJ, Balkau B, Shaw JE, Valensi P, Cailleau M, Eschwege E; on behalf of the DESIR study group. Association of glucose metabolism, smoking and cardiovascular risk factors with incident peripheral arterial disease: The DESIR study. Atherosclerosis 2007; 190: 84-89.
8. Kennedy M, Solomon C, Manolio TA, Criqui MH, Newman AB, Polak JF, et al. Risk factors for declining ankle-brachial index in men and women 65 years or older: The Cardiovascular Health Study. Arch Intern Med 2005; 165: 1896-1902.
9. Aronow WS, Ahn C. Association between plasma homocysteine and peripheral arterial disease in older persons. Coron Artery Dis 1998; 9: 49-50.
10. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285: 2481-2485.
11. Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: Clinical importance. Curr Probl Cardiol 2004; 29: 439-493.
12. Beckman JA, Preis O, Ridker PM, Gerhard-Herman M. Comparison of usefulness of inflammatory markers in patients with versus without peripheral arterial disease in predicting adverse cardiovascular outcomes (myocardial infarction, stroke, and death). Am J Cardiol 2005; 96: 1374-1378.
13. McDermott MM, Guralnik JM, Corsi A, Albay M, Macchi C, Bandinelli S, et al. Patterns of inflammation associated with peripheral arterial disease: The InCHIANTI study. Am Heart J 2005; 150: 276-281.
14. Wildman RP, Muntner P, Chen J, Sutton-Tyrrell K, He J. Relation of inflammation to peripheral arterial disease in the national health and nutrition examination survey, 1999-2002. Am J Cardiol 2005; 96: 1579-1583.
15. O'Hare AM, Bertenthal D, Shlipak MG, Sen S, Chren MM. Impact of renal insufficiency on mortality in advanced lower extremity peripheral arterial disease. J Am Soc Nephrol 2005; 16: 514-519.
16. O'Hare AM, Newman AB, Katz R, Fried LF, Stehman-Breen CO, Seliger SL, et al. Cystatin C and incident peripheral arterial disease events in the elderly: Results from the Cardiovascular Health Study. Arch Intern Med 2005; 165: 2666-2670.
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation (Modification of Diet in Renal Disease Study Group). Ann Intern Med 1999; 130: 461-470.
18. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197.
19. Kusuoka H, Hoffman JI. Advice on statistical analysis for Circulation Research. Circ Res 2002; 91: 662-671.
20. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289: 2560-2572.
21. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circutotion 2003; 107: 499-511.
22. Becker RC, Cannon CP, Bovill EG, Tracy RP, Thompson B, Knatterud GL, et al. Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction (TIMI IIIB Trial). Am J Cardiol 1996; 78: 142-147.
23. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. JAMA 2002; 288: 2015-2022.
24. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
25. Cassar K, Bachoo P, Ford I, Greaves M, Brittenden J. Markers of coagulation activation, endothelial stimulation and inflammation in patients with peripheral arterial disease. Eur J Vasc Endovasc Surg 2005; 29: 171-176.
26. Armitage JD, Lindsey NJ, Homer-Vanniasinkam S. The role of endothelial cell reactive antibodies in peripheral arterial disease. Eur J Vasc Endovasc Surg 2006; 31: 170-175.
27. Wattanakit K, Folsom AR, Selvin E, Weatherley BD, Pankow JS, Brancati FL, et al. Risk factors for peripheral arterial disease incidence in persons with diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 2005; 180: 389-397.
28. Rizzo M, Pernice V, Frasheri A, Berneis K. Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with peripheral arterial disease. Atherosclerosis 2007 May 5 [Epub ahead of print].
29. Monaco C, Crea F, Niccoli G, Summaria F, Cianflone D, Bordone R, et al. Autoantibodies against oxidized low density lipoproteins in patients with stable angina, unstable angina or peripheral vascular disease; pathophysiological implications. Eur Heart J 2001; 22: 1572-1577.
30. Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 2007; 45: 645-654.
31. Tokuno A, Hirano T, Hayashi T, Mori Y, Yamamoto T, Nagashima M, et al. The effects of statin and fibrate on lowering small dense LDL-cholesterol in hyperlipidemic patients with type 2 diabetes. J Atheroscler Thromb 2007; 14: 128-132.
32. Daskalopoulou SS, Daskalopoulos ME, Mikhailidis DP, Liapis CD. Lipid management and peripheral arterial disease. Curr Drug Targets 2007; 8: 561-570.
33. O'Hare AM, Rodriguez RA, Bacchetti P. Low ankle-brachial index associated with rise in creatinine level over time: Results from the atherosclerosis risk in communities study. Arch Intern Med 2005; 165: 1481-1485.
34. O'Hare A, Johansen K. Lower-extremity peripheral arterial disease among patients with end-stage renal disease. J Am Soc Nephrol 2001; 12: 2838-2847.
35. Mlekusch W, Exner M, Sabeti S, Amighi J, Schlager O, Wagner O, et al. Serum creatinine predicts mortality in patients with peripheral artery disease: Influence of diabetes and hypertension. Atherosclerosis 2004; 175: 361-367.
36. McDermott MM, Liu K, Guralnik JM, Ferrucci L, Green D, Greenland P, et al. Functional decline in patients with and without peripheral arterial disease: Predictive value of annual changes in levels of C-reactive protein and D-dimer. J Gerontol A Biol Sci Med Sci 2006; 61: 374-379.
37. Vainas T, Stassen FR, De Graaf R, Twiss EL, Herngreen SB, Welten RJ, et al. C-reactive protein in peripheral arterial disease: Relation to severity of the disease and to future cardiovascular events. J Vasc Surg 2005; 42: 243-251.
38. Lane JS, Vittinghoff E, Lane KT, Hiramoto JS, Messina LM. Risk factors for premature peripheral vascular disease: Results for the National Health and Nutritional Survey, 1999-2002. J Vasc Surg 2006; 44: 319-325.
39. Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol 2006; 47: 921-929.
40. Selvin E, Wattanakit K, Steffes MW, Coresh J, Sharrett AR. HbA1c and peripheral arterial disease in diabetes: The atherosclerosis risk in communities study. Diabetes Care 2006; 29: 877-882.
41. Leibson CL, Ransom JE, Olson W, Zimmerman BR, O'Fallon WM, Palumbo PJ. Peripheral arterial disease, diabetes, and mortality. Diabetes Care 2004; 27: 2843-2849.
42. Verhaeghe R. Epidemiology and prognosis of peripheral obliterative arteriopathy. Drugs 1998; 56(Suppl): 1-10.
43. Sukhija R, Aronow WS, Yalamanchili K, Peterson SJ, Frishman WH, Babu S. Association of ankle-brachial index with severity of angiographic coronary artery disease in patients with peripheral arterial disease and coronary artery disease. Cardiology 2005; 103: 158-160.
44. Chang ST, Chen CL, Chu CM, Lin PC, Chung CM, Hsu JT, et al. Ankle-arm index is a useful test for clinical practice in outpatients with suspected coronary artery disease. Circ J 2006; 70: 686-690.
45. Tseng CH. Sex difference in the distribution of atherosclerotic risk factors and their association with peripheral arterial disease in Taiwanese type 2 diabetic patients. Circ J 2007; 71: 1131-1136.
46. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286: 1317-1324.
47. Khan S, Flather M, Mister R, Delahunty N, Fowkes G, Bradbury A, et al. Characteristics and treatments of patients with peripheral arterial disease referred to UK vascular clinics: Results of a prospective registry. Eur J Vasc Endovasc Surg 2007; 33: 442-450.
48. Lawson G. The importance of obtaining ankle-brachial indexes in older adults: The other vital sign. J Vasc Nurs 2005; 23: 46-51.
49. Caruana MF, Bradbury AW, Adam DJ. The validity, reliability, reproducibility and extended utility of ankle to brachial pressure index in current vascular surgical practice. Eur J Vasc Endovasc Surg 2005; 29: 443-451.
50. Sandhu C, Belli AM, Oliveira DB. The role of N-acetylcy steine in the prevention of contrast-induced nephrotoxicity. Cardiovasc Intervent Radiol 2006; 29: 344-347.
51. Daniel JP, Chantrel F, Offner M, Moulin B, Hannedouche T. Comparison of cystatin C, creatinine and creatinine clearance vs GFR for detection of renal failure in renal transplant patients. Ren Fail 2004; 26: 253-257.
52. Kajiguchi M, Kondo T, Izawa H, Kobayashi M, Yamamoto K, Shintani S, et al. Safety and efficacy of autologous progenitor cell transplantation for therapeutic angiogenesis in patients with critical limb ischemia. Circ J 2007; 71: 196-201.
53. Arai M, Misao Y, Nagai H, Kawasaki M, Nagashima K, Suzuki K, et al. Granulocyte colony-stimulating factor: A noninvasive regeneration therapy for treating atherosclerotic peripheral artery disease. Circ J 2006; 70: 1093-1098.
54. Hasimu B, Li J, Yu J, Ma Y, Zhao M, Nakayama T, et al. Evaluation of medical treatment for peripheral arterial disease in Chinese high-risk patients. Circ J 2007; 71: 95-99.